Jesse  Goodman net worth and biography

Jesse Goodman Biography and Net Worth

Jesse Goodman brings to Intellia more than three decades of expertise in medicine and public health, including as a professor, practicing clinician and senior government leader. Jesse is currently a professor of medicine at Georgetown University, where he directs the Center on Medical Product Access, Safety and Stewardship (COMPASS). He also is an active clinician, serving as attending physician in infectious diseases.

He was the FDA’s Chief Scientist between 2009 and 2014, and previously served as the FDA’s Deputy Commissioner for Science and Public Health and as Director of the Center for Biologics Evaluation and Research (CBER). Jesse additionally helped develop the FDA’s Regulatory Science and Medical Countermeasures Initiatives and served on the Senior Leadership Team for the 2010 White House Medical Countermeasure Review. As the FDA’s Chief Scientist, he led preparations and responses to major public health threats, including emerging infectious diseases, disasters and terrorism, such as West Nile Virus and the 2009 H1N1 influenza pandemic. Previously, he was professor and chief of infectious diseases at the University of Minnesota, where his laboratory first isolated and characterized the biology of the emerging tick-borne pathogen Anaplasma phagocytophilum and where he also lead clinical trials helping to develop new anti-infective agents.

Jesse serves as an independent non-executive director for GlaxoSmithKline plc, a global pharmaceutical company; as president and trustee of the U.S. Pharmacopeial Convention; and on the Regulatory Working Group of the Coalition on Epidemic Preparedness Innovation (CEPI). Jesse graduated with an AB in biology from Harvard University; earned a master’s in public health from the University of Minnesota; and received his M.D. from the Albert Einstein College of Medicine. He completed his residency and fellowship training at the Hospital of the University of Pennsylvania and at the University of California at Los Angeles, where he was also chief medical resident. He is board-certified in internal medicine, infectious diseases and oncology and has been elected to the American Society for Clinical Investigation and to the U.S. National Academy of Medicine.

What is Jesse Goodman's net worth?

The estimated net worth of Jesse Goodman is at least $237.26 thousand as of July 1st, 2025. Dr. Goodman owns 24,359 shares of Intellia Therapeutics stock worth more than $237,257 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Goodman may own. Learn More about Jesse Goodman's net worth.

How do I contact Jesse Goodman?

The corporate mailing address for Dr. Goodman and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]. Learn More on Jesse Goodman's contact information.

Has Jesse Goodman been buying or selling shares of Intellia Therapeutics?

Jesse Goodman has not been actively trading shares of Intellia Therapeutics within the last three months. Most recently, Jesse Goodman sold 1,547 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $9.23, for a transaction totalling $14,278.81. Following the completion of the sale, the director now directly owns 24,359 shares of the company's stock, valued at $224,833.57. Learn More on Jesse Goodman's trading history.

Who are Intellia Therapeutics' active insiders?

Intellia Therapeutics' insider roster includes James Basta (EVP, General Counsel and Corporate Secretary), William Chase (Director), Eliana Clark (EVP), John Crowley (Director), Caroline Dorsa (Director), Michael Dube (CAO), Jean-Francois Formela (Director), Glenn Goddard (CFO), Jesse Goodman (Director), J III (EVP), David Lebwohl (EVP), John Leonard (CEO), Jose Rivera (EVP), Andrew Schiermeier (COO), Birgit Schultes (EVP), and Laura Sepp-Lorenzino (EVP). Learn More on Intellia Therapeutics' active insiders.

Are insiders buying or selling shares of Intellia Therapeutics?

In the last year, Intellia Therapeutics insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $1,003,000.00. In the last year, insiders at the sold shares 11 times. They sold a total of 43,701 shares worth more than $541,697.15. The most recent insider tranaction occured on October, 1st when EVP Birgit C Schultes sold 31 shares worth more than $538.78. Insiders at Intellia Therapeutics own 3.1% of the company. Learn More about insider trades at Intellia Therapeutics.

Information on this page was last updated on 10/1/2025.

Jesse Goodman Insider Trading History at Intellia Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/1/2025Sell1,547$9.23$14,278.8124,359View SEC Filing Icon  
See Full Table

Jesse Goodman Buying and Selling Activity at Intellia Therapeutics

This chart shows Jesse Goodman's buying and selling at Intellia Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intellia Therapeutics Company Overview

Intellia Therapeutics logo
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $9.74
Low: $8.85
High: $9.92

50 Day Range

MA: $15.47
Low: $8.04
High: $27.98

2 Week Range

Now: $9.74
Low: $5.90
High: $28.25

Volume

5,893,115 shs

Average Volume

6,755,643 shs

Market Capitalization

$1.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.13